187 related articles for article (PubMed ID: 15932835)
1. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women.
Ronkin S; Northington R; Baracat E; Nunes MG; Archer DF; Constantine G; Pickar JH
Obstet Gynecol; 2005 Jun; 105(6):1397-404. PubMed ID: 15932835
[TBL] [Abstract][Full Text] [Related]
2. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.
Archer DF; Pinkerton JV; Utian WH; Menegoci JC; de Villiers TJ; Yuen CK; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1109-15. PubMed ID: 19543129
[TBL] [Abstract][Full Text] [Related]
3. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
Pinkerton JV; Archer DF; Utian WH; Menegoci JC; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1102-8. PubMed ID: 19546825
[TBL] [Abstract][Full Text] [Related]
4. Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding study.
Pickar JH; Lavenberg J; Pan K; Komm BS
Menopause; 2018 Mar; 25(3):273-285. PubMed ID: 29088019
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
Palacios S; de Villiers TJ; Nardone Fde C; Levine AB; Williams R; Hines T; Mirkin S; Chines AA;
Maturitas; 2013 Sep; 76(1):81-7. PubMed ID: 23871271
[TBL] [Abstract][Full Text] [Related]
6. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
Langer RD; Landgren BM; Rymer J; Helmond FA;
Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
[TBL] [Abstract][Full Text] [Related]
7. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
[TBL] [Abstract][Full Text] [Related]
8. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.
Pickar JH; Yeh IT; Bachmann G; Speroff L
Fertil Steril; 2009 Sep; 92(3):1018-1024. PubMed ID: 19635613
[TBL] [Abstract][Full Text] [Related]
9. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.
Mirkin S; Pinkerton JV; Kagan R; Thompson JR; Pan K; Pickar JH; Komm BS; Archer DF
J Womens Health (Larchmt); 2016 May; 25(5):431-42. PubMed ID: 27058301
[TBL] [Abstract][Full Text] [Related]
10. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
11. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
[TBL] [Abstract][Full Text] [Related]
12. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.
Archer DF; Lewis V; Carr BR; Olivier S; Pickar JH
Fertil Steril; 2009 Sep; 92(3):1039-1044. PubMed ID: 19635614
[TBL] [Abstract][Full Text] [Related]
13. Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo.
Kagan R; Abreu P; Andrews E
Postgrad Med; 2018 Nov; 130(8):687-693. PubMed ID: 30280946
[TBL] [Abstract][Full Text] [Related]
14. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized, ascending, multiple-dose study of bazedoxifene in healthy postmenopausal women.
McKeand WE; Orczyk GP; Ermer JC; Chines AA
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):262-9. PubMed ID: 27128831
[TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis.
de Villiers TJ
Climacteric; 2010 Jun; 13(3):210-8. PubMed ID: 20184423
[TBL] [Abstract][Full Text] [Related]
17. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial.
Rutanen EM; Heikkinen J; Halonen K; Komi J; Lammintausta R; Ylikorkala O
Menopause; 2003; 10(5):433-9. PubMed ID: 14501605
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S
J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
[TBL] [Abstract][Full Text] [Related]
19. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women.
Draper MW; Plouffe L
Obstet Gynecol; 2005 Nov; 106(5 Pt 1):1110-1; author reply 1111. PubMed ID: 16260540
[No Abstract] [Full Text] [Related]
20. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
Pinkerton JV; Pickar JH; Racketa J; Mirkin S
Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]